Sector
PharmaceuticalsOpen
₹6,727Prev. Close
₹6,697.4Turnover(Lac.)
₹25,383.54Day's High
₹6,755Day's Low
₹6,632.352 Week's High
₹7,107.4552 Week's Low
₹5,205.55Book Value
₹1,543.48Face Value
₹5Mkt Cap (₹ Cr.)
1,11,180.1P/E
26.98EPS
246.88Divi. Yield
0.67 May 2024
12:00 AM
BookCloser
7 May 2024
12:00 AM
AGM
Announcement Date: 07 May, 2024
7 May 2024
12:00 AM
Dividend
Dividend Amount: 40
21 Jun 2024
12:00 AM
Board Meeting
Agenda : Audited Result
Here are some of the stocks that may see significant price movement today: Mazagon Dock Shipbuilders, Krsnaa Diagnostics, Dr Reddy's, etc.
The experiment also had a favourable safety profile, with no serious adverse effects such as Cytokine Release Syndrome (CRS) or neurotoxicity reported.
The agreement also includes a provision for Dr. Reddy’s to manufacture and commercialize Lenacapavir for HIV prevention (PrEP) in the same 120 countries, pending approval.
Here are some of the stocks that may see significant price movement today: Welspun Enterprises, IDFC First Bank, Dr Reddy’s Laboratories, etc.
This inspection success at Bachupally, combined with steady financial performance, reinforces Dr Reddy's position as a key player in the pharmaceutical industry.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | -15.7 | -43.6 | -76.9 | -113.5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 24,256.5 | 20,517.8 | 18,413.1 | 17,097.2 |
Net Worth | 24,240.8 | 20,474.2 | 18,336.2 | 16,983.7 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 14,405.2 | 13,349.1 | 11,850.4 | 9,359.3 |
yoy growth (%) | 7.91 | 12.64 | 26.61 | -3.7 |
Raw materials | -5,045.9 | -4,123 | -3,573.8 | -2,631 |
As % of sales | 35.02 | 30.88 | 30.15 | 28.11 |
Employee costs | -2,434.6 | -2,270.1 | -2,030.2 | -1,843 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 2,223.8 | 3,056.2 | 2,775.8 | 696.99 |
Depreciation | -814.3 | -835 | -789.2 | -774.1 |
Tax paid | -600.6 | -869.8 | 161.9 | -130.1 |
Working capital | 1,395.8 | 1,078.3 | 508.8 | -170.1 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 7.91 | 12.64 | 26.61 | -3.7 |
Op profit growth | -17.3 | 9.31 | 115.77 | -23.81 |
EBIT growth | -27.1 | 9.89 | 271.62 | -52.56 |
Net profit growth | -25.75 | -25.57 | 418.2 | -59.04 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 27,916.4 | 24,587.9 | 21,439.1 | 18,972.2 | 17,460 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 27,916.4 | 24,587.9 | 21,439.1 | 18,972.2 | 17,460 |
Other Operating Income | 94.7 | 81.8 | 106.1 | 75.3 | 57 |
Other Income | 909 | 1,092.5 | 554.7 | 339.4 | 676.7 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,887.55 | 162.64 | 4,52,670.53 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,817.95 | 93.02 | 1,54,512 | 430 | 0.51 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,510.35 | 30.73 | 1,22,039.52 | 1,055.94 | 0.86 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,339.65 | 75.14 | 1,12,925.71 | 469 | 0.84 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,662.4 | 26.98 | 1,11,144.22 | 1,417.2 | 0.6 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Co-Chairman & Managing Directo
G V Prasad
Executive Chairman
K Satish Reddy
Independent Director
Shikha Sanjaya Sharma
Lead Independent Director
Leo Puri
Independent Director
K P Krishnan
Independent Director
Pennv Wan
Company Sec. & Compli. Officer
K Randhir Singh
Independent Director
Arun M. Kumar
Independent Director
Claudio Albrecht
Independent Director
Sanjiv Mehta
Independent Director
Alpna Seth
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Dr Reddys Laboratories Ltd
Summary
Dr Reddys Laboratories Ltd (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddys offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The companys major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddys operates in markets across the globe. Its major markets include - USA, India, Russia & CIS countries, and Europe.Dr Reddys Laboratories was incorporated in the year 1984 in Hyderabad. The company was established by Dr Anji Reddy with an initial capital outlay of Rs 25 lakh. The company made their beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (API) and commenced operations with a single drug in a 60-tonne facility near Hyderabad, India. In the year 1986, the company shares were listed on the Bombay Stock Exchange. Also, they entered international market with exports of Methyldopa.In the year 1987, the company obtained first USFDA approval for Ibuprofen API. In the year 1988, they acquired Benzex Laboratories Pvt Ltd to expand their Bulk Actives business. In the year 1990, they exported Norfloxacin and Ciprofloxacin to Europe
Read More
What is the Dr Reddys Laboratories Ltd share price today?
The Dr Reddys Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹6662.4 today.
What is the Market Cap of Dr Reddys Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dr Reddys Laboratories Ltd is ₹111180.10 Cr. as of 22 Oct ‘24
What is the PE and PB ratio of Dr Reddys Laboratories Ltd?
The PE and PB ratios of Dr Reddys Laboratories Ltd is 26.98 and 4.57 as of 22 Oct ‘24
What is the 52 Week High and Low of Dr Reddys Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Dr Reddys Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Dr Reddys Laboratories Ltd is ₹5205.55 and ₹7107.45 as of 22 Oct ‘24
What is the CAGR of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd's CAGR for 5 Years at 18.84%, 3 Years at 12.84%, 1 Year at 20.00%, 6 Month at 10.74%, 3 Month at -1.60% and 1 Month at 0.12%.
What is the shareholding pattern of Dr Reddys Laboratories Ltd?
The shareholding pattern of Dr Reddys Laboratories Ltd is as follows:
Promoters - 26.65 %
Institutions - 62.99 %
Public - 10.19 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
